In an interview by IdeaMensch dated April 14th, 2017 Clay Siegall provided great insight about his role as CEO of Seattle Genetics. Motivated by his father’s battle with cancer which began when he was only nineteen years old; Clay Siegall noticed that the resources doctor’s had been very limited. He eventually pursued a Ph.D. with George Washington University. While Siegall is certainly an entrepreneur, he credits himself as being a scientist first and foremost. His goal of helping patients with drugs that are targeted specifically to their needs has been in practice for thirty years. Recently, Seattle Genetics has been paving the way with antibody-drug conjugates, which have yielded a new drug called ADCTERIS, produced by Takeda Pharmaceutical Company. The company continues to develop proprietary drugs along these (same) lines.
Siegall’s business acumen has also made it possible to secure financing of over 1.2 billion dollars. His company was founded in 1998 and was made public in 2001. He is not only the CEO of Seattle Genetics but also on the board of directors at Mirna, a company focusing on microRNA therapeutics and Alder BioPharmaceuticals. Prior to starting his own company, Siegall worked for drug and research giant Bristol-Myers Squibb Pharmaceutical Research Institute and the National Cancer Institute, National Institutes of Health. To top off his already extensive resume, he has authored over 70 publications and has patented his work over 15 times.
Siegall’s work(s) have not gone unnoticed. He’s earned many accolades including 2013 Alumnus of the Year Award for Computer, Math, and Science(s) from the University of Maryland where he earned his B.S. in Zoology. He’s been distinguished as the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012. He’s also known for having partnered with many other pharmaceutical companies to make his technology and research widespread to make even faster advances. Siegall’s efforts, knowledge, and experience, as well as his business expertise, make him stand out among the Biotech and Pharmaceutical companies and his hard work and dedication are making rapid advances in cancer therapy possible.